CA125 ELISA

Key Features and Values

– Same sample type can be used across all assays to simplify inclusion into routine serology work-up
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a complete panel of assays for supporting treatment monitoring of several forms of cancer

Product Description

CA125 ELISA kit is an immunoenzymatic colorimetric method for the quantitative determination of the tumoral antigen CA125 concentration in human serum or plasma. CA125 ELISA kit is intended for laboratory use only.

Scientific Description
CA125 is a tumour marker, it is a glycoprotein as high molecular weight entity (MW > 200,000).  It is best known as a marker for ovarian cancer, but it may also be elevated in other malignant cancers, including those originating in the endometrium, fallopian tubes, lungs, breast and gastrointestinal tract.  CA125 may also be elevated in a number of relatively benign conditions, such as endometriosis, several diseases of the ovary and pregnancy.  It also tends to be elevated in the presence of any inflammatory condition in the abdominal area, both cancerous and benign.  Thus, CA125 is not perfectly specific for cancer nor is it perfectly sensitive since not every patient with cancer will have elevated levels of CA125 in the blood.
CA125 is clinically approved for monitoring the response to treatment and predicting prognosis after treatment.  It is especially useful for detecting the recurrence of ovarian cancer.  Its potential role for the early detection of ovarian cancer is controversial and has not yet been adopted for widespread screening efforts in asymptomatic women.
Elevated levels in post-menopausal women are usually an indication that further screening is necessary.  In pre-menopausal women, the test is less reliable as values are often elevated due to a number of non-cancerous causes.
Publications

1. Zamcheck N, Adv Intern Med, 19, 413 (1974)
2. Rayncao G, Chu TM, JAMA, 220, 381 (1972)
3. Harrison, Priciples of Internal Medicine., McGraw Hill Book Company, New York. 12th. Ed.
4. Wild D, The Immunoassay Handbook., Stockton Press (1994)
5. Hasholzner U, Tumor Diagnosis & Ther 15:114-117 (1994)
6. Hasholzner U, Int J Cancer 69:329-34 (1996)
7. Ovarian Cancer–NIH Conference. JAMA 273:491-497 (1995)
8. Daoud E. Clin Chem 37:1968-74 (1991)
9. De Bruijn HWA, Curr Opin Gynecol 9:8-13 (1997)
10. Sikorska H, Cancer Detection Preview 12:321-355 (1988)
11. NIH CA125 Ann.Inter.Med. 94:407-409 (1981)

Download
Please enter your email address to download the DKO054-CA125-IFU.pdf
Code: DKO054
Clinical Area:
Incubation: 60+15 min
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum/Plasma
Sample Volume: 25 μL
Assay Range: 15 - 400 U/mL